Novel strategies for the treatment of acetaminophen hepatotoxicity

Area of Science:

• Hepatology
• Toxicology
• Pharmacology

Background:

• Acetaminophen (APAP) overdose is a primary cause of acute liver failure globally.
• N-acetylcysteine is the sole current antidote, highlighting the need for new therapeutic strategies.
• Recent research focuses on translating mechanistic insights into novel drug targets for APAP hepatotoxicity.

Purpose of the Study:

• To review the pathophysiology of APAP-induced liver injury and recovery.
• To evaluate potential therapeutic targets and new drugs for APAP hepatotoxicity.
• To discuss the clinical utility of existing and emerging treatments.

Main Methods:

• Review of key events in APAP hepatotoxicity.
• Discussion of pros and cons of targeting specific pathophysiological steps.
• Consideration of repurposed drugs, novel entities, and herbal medicine extracts.

Main Results:

• Fomepizole (4-methylpyrazole) demonstrates safety and efficacy in preclinical models, human hepatocytes, and volunteers.
• Calmangafodipir shows safety in patients but requires robust preclinical efficacy data.
• Herbal medicine studies exhibit poor experimental design, questioning their clinical relevance.

Conclusions:

• Fomepizole is a promising candidate for APAP overdose, pending Phase III trials.
• Calmangafodipir requires further validation before regulatory consideration.
• The clinical utility of herbal remedies for APAP overdose remains uncertain due to study limitations.